Novo Nordisk to discontinue Levemir insulin by end of 2026

Novo Nordisk has announced that it will discontinue Levemir insulin by the end of 2026. If you currently use Levemir, this news may be concerning, but there are plans in place to help you transition smoothly to an alternative.

What’s being done to help?

The Department of Health and Social Care (DHSC), NHS England, and clinical experts are working together to provide guidance and support. A Medicines Supply Notification has been issued to help prescribers understand what alternative options are available.

What you need to do

We understand that changes to medication can be unsettling, but there is time to discuss your options. The withdrawal date at the end of 2026 gives you and your healthcare professional the opportunity to find the best alternative for you.

If you do not already have a diabetes appointment scheduled before the end of November 2026, contact your diabetes healthcare team to understand when your insulin will be reviewed.

Many people across the UK will need to make this change, so appointments are likely to take place over a number of months. In some cases, services may offer group appointments. If you are not contacted straight away, there is no need to be concerned.

You can also:

• Speak to your diabetes team or GP at your next routine appointment about suitable alternative insulins and when your prescription may be updated
• Contact your diabetes team directly if you are on a Patient‑Initiated Follow‑Up (PIFU) pathway
• Look out for messages from your healthcare provider, which will explain how this change is being managed locally and when you should book an appointment

Your healthcare team will guide you through this process and help you move to an insulin that is right for you based on your current treatment. They’ll make sure you’re trained on any new device, understand your dose, and feel confident managing your blood glucose. If you have any questions, please raise them with your healthcare team during your appointment.